Shares of Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) hit a new 52-week high on Friday . The company traded as high as $15.84 and last traded at $15.79, with a volume of 208,923 shares. The stock had previously closed at $15.41.

LXRX has been the topic of a number of research reports. Needham & Company LLC reissued a “buy” rating and set a $21.00 target price on shares of Lexicon Pharmaceuticals in a report on Wednesday, May 4th. JPMorgan Chase & Co. reissued a “hold” rating and set a $16.00 target price on shares of Lexicon Pharmaceuticals in a report on Thursday, May 5th. Cowen and Company reissued a “market perform” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, May 3rd. Wedbush reissued an “outperform” rating and set a $28.00 target price on shares of Lexicon Pharmaceuticals in a report on Friday, May 6th. Finally, Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 6th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $18.50.

The stock’s market cap is $1.64 billion. The firm has a 50 day moving average price of $14.39 and a 200-day moving average price of $12.35.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.04. The business earned $12.50 million during the quarter, compared to the consensus estimate of $11.11 million. During the same quarter in the previous year, the business posted ($0.04) EPS. The firm’s revenue was up 594.4% on a year-over-year basis. Equities analysts expect that Lexicon Pharmaceuticals Inc. will post ($1.55) earnings per share for the current year.

In other Lexicon Pharmaceuticals news, VP James F. Tessmer sold 6,000 shares of the stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $13.00, for a total transaction of $78,000.00. Following the transaction, the vice president now owns 21,946 shares in the company, valued at $285,298. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Several large investors recently made changes to their positions in the company. New York State Common Retirement Fund increased its stake in shares of Lexicon Pharmaceuticals by 240.2% in the fourth quarter. New York State Common Retirement Fund now owns 177,168 shares of the biopharmaceutical company’s stock valued at $2,358,000 after buying an additional 125,083 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of Lexicon Pharmaceuticals by 7.7% in the fourth quarter. ProShare Advisors LLC now owns 89,382 shares of the biopharmaceutical company’s stock valued at $1,190,000 after buying an additional 6,390 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Lexicon Pharmaceuticals by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 76,947 shares of the biopharmaceutical company’s stock valued at $1,024,000 after buying an additional 1,372 shares during the last quarter. Finally, Nationwide Fund Advisors increased its stake in shares of Lexicon Pharmaceuticals by 124.1% in the fourth quarter. Nationwide Fund Advisors now owns 139,876 shares of the biopharmaceutical company’s stock valued at $1,862,000 after buying an additional 77,446 shares during the last quarter.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.